^
PIK3CA mutation
Squamous Cell Carcinoma of Head and Neck
PD1 inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
TERT mutation
Squamous Cell Carcinoma of Head and Neck
PD1 inhibitor
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
Chr amplification(15)(q22.31)
Squamous Cell Carcinoma of Head and Neck
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Squamous Cell Carcinoma of Head and Neck
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
nivolumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
TPF
Sensitive
:
A1
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
methotrexate
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
methotrexate
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
TPeX
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
ADX-2191
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive
:
A2
No biomarker
Squamous Cell Carcinoma of Head and Neck
TPeX
Sensitive
:
A2
No biomarker
Squamous Cell Carcinoma of Head and Neck
cisplatin
Sensitive
:
A2
No biomarker
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive
:
A2
No biomarker
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + nivolumab
Sensitive
:
A2
No biomarker
Squamous Cell Carcinoma of Head and Neck
carboplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Squamous Cell Carcinoma of Head and Neck
AT-406
Sensitive
:
B
CDKN2A negative
Squamous Cell Carcinoma of Head and Neck
panitumumab
Sensitive
:
B
HRAS mutation
Squamous Cell Carcinoma of Head and Neck
tipifarnib
Sensitive
:
B
TMB-H
Squamous Cell Carcinoma of Head and Neck
durvalumab
Sensitive
:
B
TMB-H
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
B
TMB-H
Squamous Cell Carcinoma of Head and Neck
durvalumab + CP-675206
Sensitive
:
B
KMT2D mutation
Squamous Cell Carcinoma of Head and Neck
durvalumab + CP-675206
Sensitive
:
B
EGFR amplification
Squamous Cell Carcinoma of Head and Neck
afatinib
Sensitive
:
B
ERBB3-L
Squamous Cell Carcinoma of Head and Neck
afatinib
Sensitive
:
B
CDKN2A negative
Squamous Cell Carcinoma of Head and Neck
afatinib
Sensitive
:
B
PTEN-H
Squamous Cell Carcinoma of Head and Neck
afatinib
Sensitive
:
B
PD-L1 overexpression
Squamous Cell Carcinoma of Head and Neck
durvalumab
Sensitive
:
B